Low prevalence of asthma in Mexican children and adults with a positive rtRT-PCR test for SARS-CoV-2: a cross-sectional study during the 2020 pandemic

Main Article Content

Martín Bedolla-Barajas
Jaime Morales-Romero https://orcid.org/0000-0002-1492-1797
Tonatiuh Ramses Bedolla-Pulido https://orcid.org/0000-0002-5292-0728
Carlos Meza-López https://orcid.org/0000-0002-8720-4289
Martín Robles-Figueroa https://orcid.org/0000-0003-3984-9928
Norma Angélica Pulido-Guillén
Luis Gustavo Orozco-Alatorre https://orcid.org/0000-0002-3037-5124
Carlos Alberto Andrade-Castellanos https://orcid.org/0000-0003-4720-3289


Asthma, COVID-19, Cross-sectional study, Children, Adult


Background: It has recently been argued that asthma does not increase the risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. If so, the prevalence of asthma in subjects diagnosed with COVID-19 should be lower than in the general population.

Objective: To determine the prevalence of asthma in Mexican children and adults with SARS-CoV-2 infection.
Methods: A public database of the Epidemiological Surveillance System for Viral Respiratory Disease in Mexico was analyzed. Those who underwent the real-time reverse transcriptase-polymerase chain reaction-SARS-CoV-2 (rtRT-PCR-SARS-CoV-2) test from February 27 to June 21, 2020, were included. In addition to the prevalence of asthma, some factors associated with it were investigated.

Results: Data from 417,366 subjects were analyzed. Asthma prevalence in children, adults, and global were 3.7%, 3.3%, and 3.3%, respectively. Although the asthma prevalence was lower in SARS-CoV-2 positive over negative patients, significant differences were only found in adults (2.8% vs. 3.7% respectively; odds ratio (OR) = 0.74; 95% confidence interval (CI): 0.71–0.77); but not in children (3.5% vs. 3.8%, respectively; OR = 0.91; 95%CI: 0.76–1.10). Multivariate analysis showed in younger than 18 years that girls and immunosuppression were factors associated with a decrease in the odds to develop asthma. In adults, asthma was positively associated with females, obesity, smoking, immunosuppression, chronic obstructive pulmonary disease, arterial hypertension, and cardiovascular disease.

Abstract 104 | PDF Downloads 80 XML Downloads 0 HTML Downloads 1


1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and inju-ries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211– 59. https://doi.org/10.1016/S0140-6736(17)32154-2
2. Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S, et al. Global variation in the prevalence and severity of asthma symptoms: Phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009;64:476–83. https://doi.org/10.1136/thx.2008.106609
3. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: Findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204. https://doi.org/10.1186/1471-2458-12-204
4. Al Huraimel K, Alhosani M, Kunhabdulla S, Stietiya MH. SARS-CoV-2 in the environment: Modes of transmission, early detection and potential role of pollutions. Sci Total Environ. 2020;744:140946. https://doi.org/10.1016/j.scitotenv. 2020.140946
5. Novak N, Cabanillas B. Viruses and asthma: The role of com-mon respiratory viruses in asthma and its potential meaning for SARS-CoV-2. Immunology. 2020;161(2):83–93. https://doi. org/10.1111/imm.13240
6. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020; 41(2):113–22. Chinese. https://doi. org/10.3760/cma.j.issn.0254-6450.2020.02.003.
7. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146:110–18. https://doi.org/10.1016/j.jaci.2020.04.006
8. Mancilla-Hernández E, González-Solórzano EVM, Medina-Ávalos MÁ, Barnica- Alvarado RH. Prevalencia de asma y sus síntomas en población escolar de Cuernavaca, Morelos, México [Prevalence of asthma and its symptoms in school-children from Cuernavaca, Morelos, Mexico]. Rev Alerg Mex. 2016;63:351–57. Spanish. https://doi.org/10.29262/ram. v63i4.189
9. Bedolla-Barajas M, Javier Ramírez-Cervantes F, Morales-Romero J, Jesús Pérez-Molina J, Meza-López C, Delgado-Figueroa N. A rural environment does not protect against asthma or other allergic diseases amongst Mexican chil-dren. Allergol Immunopathol. 2018;46:31–38. https://doi. org/10.1016/j.aller.2017.01.010
10. Morales-Romero J, Bedolla-Barajas M, López-Cota GA, Bedolla-Pulido TI, Bedolla-Pulido TR, Navarro-Lozano E, et al. Tendencia de la prevalencia de asma y sus síntomas en los adolescentes tardíos mexicanos en un periodo de siete años [Trends in the prevalence of asthma and its symptoms in Mexican late adolescents over a 7-year period]. Rev Alerg Mex. 2018;65:331–40. Spanish. https://doi.org/10.29262/ram. v65i4.392
11. Del-Rio-Navarro BE, Navarrete-Rodríguez EM, Berber A, Reyes-Noriega N, García-Marcos Álvarez L; et al. The burden of asthma in an inner-city area: A historical review 10 years after Isaac. World Allergy Organ J. 2020;13:100092. https:// doi.org/10.1016/j.waojou.2019.100092
12. García-Sancho C, Fernández-Plata R, Martínez-Briseño D, Franco-Marina F, Pérez-Padilla JR. Prevalencia y riesgos aso-ciados con pacientes adultos con asma de 40 años o más de la Ciudad de México: Estudio de base poblacional [Prevalence and risks associated with adult patients with asthma aged 40 years or more from Mexico City: A population-based study]. Salud Publica Mex. 2012;54:425–32. Spanish. https://doi. org/10.1590/s0036-36342012000400013
13. Bedolla-Barajas M, Valdez-López F, Alcalá-Padilla G, Bedolla-Pulido TI, Rivera-Mejia V, Morales-Romero J. Prevalence and factors associated to peanut allergy in Mexican school children. Allergol Immunopathol. 2017;45:69–76. https://doi.org/10. 1016/j.aller.2016.04.013
14. Bedolla-Barajas M, Macriz-Romero N, Jara-Ettinger AC, Macriz-Romero M, Fregoso-Fregoso M, Morales-Romero J. Autorreporte de alergia al látex en estudiantes de medicina: Prevalencia y factores asociados [Self-report of latex allergy in medical students: Prevalence and associated factors]. Rev Alerg Mex. 2018;65:10–18. Spanish. https://doi.org/10.29262/ ram.v65i1.290
15. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020;8:436–8. https://doi. org/10.1016/S2213-2600(20)30167-3
16. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA Jr, Liang L. Association of asthma and its genetic predisposition with the risk of severe COVID-19. J Allergy Clin Immunol. 2020;46(2):327-9.e4.. https://doi.org/10.1016/j.jaci. 2020.06.001
17. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020;146:203–206.e3. https://doi.org/10.1016/j. jaci.2020.04.009
18. Abiad HF, Alameddine VM, Hallit S, Torbey P-H, Mroueh S, Yazbek N, et al. Aeroallergen sensitization in Lebanese asthmatic children: the results of a cohort national study. Environ Sci Pollut Res Int. 2020;27:5597–605. https://doi.org/10.1007/ s11356-019-07234-z
19. Kwizera R, Wadda V, Mugenyi L, Aanyu-Tukamuhebwa H, Nyale G, Yimer G, et al. Skin prick reactivity among asthmatics in East Africa. World Allergy Organ J. 2020;13:100130. https://doi.org/10.1016/j.waojou.2020.100130
20. Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75:1730–41. https://doi.org/10.1111/all.14238
21. Green I, Merzon E, Vinker S, Golan-Cohen A, Magen E. COVID-19 susceptibility in bronchial asthma. J Allergy Clin Immunol Pract. 2021; 9(2):684–92. . https://doi.org/10.1016/j. jaip.2020.11.020.
22. Grandbastien M, Piotin A, Godet J, Abessolo-Amougou I, Ederlé C, Enache I, et al. SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation. J Allergy Clin Immunol Pract. 2020;8:2600-7. https://doi.org/10.1016/j.jaip.2020.06.032.
23. Chhiba KD, Patel GB, Vu THT, Chen MM, Guo A, Kudlaty E, et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol. 2020;146:307–314.e4. https://doi.org/10.1016/j. jaci.2020.06.010.
24. Lieberman-Cribbin W, Rapp J, Alpert N, Tuminello S, Taioli E. The impact of asthma on mortality in patients with COVID-19. Chest. 2020; 158(6): 2290–1. https://doi.org/10.1016/j. chest.2020.05.575.